Researchers praise ‘stunning’ results of new prostate cancer treatment - The Guardian
Researchers praise ‘stunning’ results of new prostate cancer treatment The Guardian
Prostate Cancer News
A potential immunotherapy strategy for early-stage prostate cancer - Medical Xpress
A potential immunotherapy strategy for early-stage prostate cancer Medical Xpress
VIR-5500: New prostate cancer drug showing ‘remarkable’ results during clinical trial - The Independent
VIR-5500: New prostate cancer drug showing ‘remarkable’ results during clinical trial The Independent
Immunotherapy uses invisibility cloak to deliver direct hit to prostate cancer - The Institute of Cancer Research (ICR)
Immunotherapy uses invisibility cloak to deliver direct hit to prostate cancer The Institute of Cancer Research (ICR)
Innovative prostate cancer treatment shows ‘remarkable’ results - The Independent
Innovative prostate cancer treatment shows ‘remarkable’ results The Independent
‘Search and destroy’ treatment halts incurable prostate cancer - The Telegraph
‘Search and destroy’ treatment halts incurable prostate cancer The Telegraph
Ginkgo divests biosecurity arm; J&J’s early prostate cancer data - Endpoints News
Ginkgo divests biosecurity arm; J&J’s early prostate cancer data Endpoints News
How Can Novel Immunotherapies Bolster Radiotherapy in Prostate Cancer? - CancerNetwork
How Can Novel Immunotherapies Bolster Radiotherapy in Prostate Cancer? CancerNetwork
Cabazitaxel Adds No Survival Benefit in High-Risk Prostate Cancer - CUREtoday.com
Cabazitaxel Adds No Survival Benefit in High-Risk Prostate Cancer CUREtoday.com
A New Therapeutic Era in Metastatic Castration-Resistant Prostate Cancer - Pharmacy Times
A New Therapeutic Era in Metastatic Castration-Resistant Prostate Cancer Pharmacy Times
Microplastics found in 90% of prostate cancer tumors, study reveals - ScienceDaily
Microplastics found in 90% of prostate cancer tumors, study reveals ScienceDaily
Microplastics Found in 90 Percent of Prostate Cancer Samples - The ASCO Post
Microplastics Found in 90 Percent of Prostate Cancer Samples The ASCO Post
Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer - Vir Biotechnology
Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer Vir Biotechnology
San Diego Supercomputer Center Powers AI Model to Improve Prostate Cancer Care - UC San Diego Today
San Diego Supercomputer Center Powers AI Model to Improve Prostate Cancer Care UC San Diego Today
Radium‑223 (Xofigo) Plus Enzalutamide (Xtandi) Boosts Survival in Metastatic Prostate Cancer - Oncology News Central
Radium‑223 (Xofigo) Plus Enzalutamide (Xtandi) Boosts Survival in Metastatic Prostate Cancer Oncology News Central
Dr Madan on Enzalutamide Monotherapy in Biochemically Recurrent Prostate Cancer - OncLive
Dr Madan on Enzalutamide Monotherapy in Biochemically Recurrent Prostate Cancer OncLive
Daro-PET: PSMA PET After Short-Course Darolutamide in Prostate Cancer - Targeted Oncology
Daro-PET: PSMA PET After Short-Course Darolutamide in Prostate Cancer Targeted Oncology
Stacy Loeb, MD, on microplastics and prostate cancer - Urology Times
Stacy Loeb, MD, on microplastics and prostate cancer Urology Times
New real‑world data reinforce earlier use of Pluvicto® before chemotherapy in metastatic castration-resistant prostate cancer - Novartis
New real‑world data reinforce earlier use of Pluvicto® before chemotherapy in metastatic castration-resistant prostate cancer Novartis
Truqap Plus Zytiga Maintains Quality of Life in PTEN-Deficient Prostate Cancer - CUREtoday.com
Truqap Plus Zytiga Maintains Quality of Life in PTEN-Deficient Prostate Cancer CUREtoday.com
Examining Pembrolizumab Combo Safety in High-Risk Prostate Cancer - CancerNetwork
Examining Pembrolizumab Combo Safety in High-Risk Prostate Cancer CancerNetwork
Cabazitaxel Plus ADT/Radiotherapy Fails to Show Long-Term Survival Benefit in High-Risk Localized Prostate Cancer - OncLive
Cabazitaxel Plus ADT/Radiotherapy Fails to Show Long-Term Survival Benefit in High-Risk Localized Prostate Cancer OncLive
David Wise, MD, outlines early data on pasritamig in mCRPC - Urology Times
David Wise, MD, outlines early data on pasritamig in mCRPC Urology Times
ASCO GU 2026 Day One Update: Advancements in Prostate Cancer Treatment - CUREtoday.com
ASCO GU 2026 Day One Update: Advancements in Prostate Cancer Treatment CUREtoday.com
Xtandi Plus Xofigo May Help Men with Advanced Prostate Cancer Live Longer - CUREtoday.com
Xtandi Plus Xofigo May Help Men with Advanced Prostate Cancer Live Longer CUREtoday.com
Dr Loeb on Microplastics in Prostate Cancer Tissue Samples - OncLive
Dr Loeb on Microplastics in Prostate Cancer Tissue Samples OncLive
SBRT May Beat Brachytherapy in Prostate Cancer - Medscape
SBRT May Beat Brachytherapy in Prostate Cancer Medscape
Targeted radiotherapy injection shrinks treatment-resistant prostate cancer tumours in early clinical trial - The Institute of Cancer Research (ICR)
Targeted radiotherapy injection shrinks treatment-resistant prostate cancer tumours in early clinical trial The Institute of Cancer Research (ICR)
Dr Mota on Using Darolutamide to Enhance PSMA Expression in Localized Prostate Cancer - OncLive
Dr Mota on Using Darolutamide to Enhance PSMA Expression in Localized Prostate Cancer OncLive
This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug - Barron's
This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug Barron's
Adjuvant immunotherapy + hormone therapy may counteract immune-suppression in early-stage prostate cancer, Mayo-led study finds - The Cancer Letter
Adjuvant immunotherapy + hormone therapy may counteract immune-suppression in early-stage prostate cancer, Mayo-led study finds The Cancer Letter
Atlanta Hawks Foundation and Ressler Gertz Family Foundation Advance Prostate Cancer Awareness with $150,000 Gift - NBA
Atlanta Hawks Foundation and Ressler Gertz Family Foundation Advance Prostate Cancer Awareness with $150,000 Gift NBA
Enzalutamide and Radium-233 Extend Survival in Metastatic Castration-Resistant Prostate Cancer - Pharmacy Times
Enzalutamide and Radium-233 Extend Survival in Metastatic Castration-Resistant Prostate Cancer Pharmacy Times
Combination therapy may help overcome barrier in early-stage prostate cancer treatment - News-Medical
Combination therapy may help overcome barrier in early-stage prostate cancer treatment News-Medical
Frontline Abiraterone/Olaparib Doubles PFS in Biomarker-Selected mCRPC - Targeted Oncology
Frontline Abiraterone/Olaparib Doubles PFS in Biomarker-Selected mCRPC Targeted Oncology
Prostate Cancer: Surgery vs. Radiation Treatment Options - Cedars-Sinai
Prostate Cancer: Surgery vs. Radiation Treatment Options Cedars-Sinai
Astellas, Vir Biotechnology Launch Up-to-$1.7B Prostate Cancer Collaboration - GEN - Genetic Engineering and Biotechnology News
Astellas, Vir Biotechnology Launch Up-to-$1.7B Prostate Cancer Collaboration GEN - Genetic Engineering and Biotechnology News
177Lu-PSMA-617 Therapy Combo Maintains Quality of Life and Pain Control in mHSPC - CUREtoday.com
177Lu-PSMA-617 Therapy Combo Maintains Quality of Life and Pain Control in mHSPC CUREtoday.com
Free prostate cancer screening event - FOX 9 Minneapolis-St. Paul
Free prostate cancer screening event FOX 9 Minneapolis-St. Paul
Study Questions Use of Prostate Cancer Hormone Therapy in Certain Cases - MedPage Today
Study Questions Use of Prostate Cancer Hormone Therapy in Certain Cases MedPage Today